BioCentury
ARTICLE | Company News

Dynavax restructuring news

January 20, 2017 10:45 PM UTC

Dynavax will reduce headcount by 100 (38%) to 164 and will focus on its immuno-oncology pipeline. The company said the cuts would come from manufacturing support and SG&A positions. SD-101, an immunostimulatory sequence (ISS)-based second-generation type C toll-like receptor 9 (TLR9) agonist, in combination with Keytruda pembrolizumab is in Phase I/II testing to treat metastatic melanoma. DV281, a TLR9 agonist, is in preclinical testing to treat lung cancer, with Phase I testing slated next quarter.

Dynavax also suspended manufacturing of Heplisav-B, an HBV vaccine combining hepatitis B surface antigen (HBsAg) with a TLR9 agonist. This month, Dynavax plans to respond to complete response letter from FDA for a BLA for Heplisav-B. The company is seeking a partner for the product (see BioCentury, Nov. 21, 2016)...